留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

垂体腺瘤临床诊治进展

朱惠娟 王任直

朱惠娟, 王任直. 垂体腺瘤临床诊治进展[J]. 协和医学杂志, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007
引用本文: 朱惠娟, 王任直. 垂体腺瘤临床诊治进展[J]. 协和医学杂志, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007
Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007
Citation: Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007

垂体腺瘤临床诊治进展

doi: 10.3969/j.issn.1674-9081.2020.05.007
详细信息
    通讯作者:

    朱惠娟  电话:010-69155073,E-mail: shengxin2004@126.com

  • 中图分类号: R651; R584

Clinical Diagnosis and Treatment of Pituitary Adenomas

More Information
  • 摘要: 垂体腺瘤是较常见的神经内分泌肿瘤,多为良性,但其高分泌激素或大腺瘤干扰腺垂体及周围组织器官的正常功能,严重影响患者的健康和预后。多学科参与的规范诊疗是垂体腺瘤临床应对的重要原则。2017年世界卫生组织第4次修订了垂体腺瘤的病理诊断分类,高危垂体腺瘤和难治性垂体腺瘤依然是临床诊治的难点,存在诸多挑战,而垂体腺瘤的发生机制和潜在治疗靶点亦有待进一步揭示。本文系统总结了垂体腺瘤的发病机制和临床诊治进展。
    利益冲突:无
  • [1] Gittleman H, Ostrom QT, Farah PD, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004—2009[J]. J Neurosurg, 2014, 121:527-535. doi:  10.3171/2014.5.JNS131819
    [2] Orija IB, Weil RJ, Hamrahian AH. Pituitary incidentaloma[J].Best Pract Res Clin Endocrinol Metab, 2012, 26: 47-68. doi:  10.1016/j.beem.2011.07.003
    [3] Fernández-Balsells MM, Murad MH, Barwise A, et al.Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis[J]. J Clin Endocrinol Metab, 2011, 96:905-912. doi:  10.1210/jc.2010-1054
    [4] Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene[J].Science, 2006, 312: 1228-1230. doi:  10.1126/science.1126100
    [5] Schöfl C, Jürgen H, Michael D, et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study[J].J Clin Endocrinol Metab, 2014, 99: E2789-E2793. doi:  10.1210/jc.2014-2094
    [6] Yao Y, Liu Y, Wang LJ, et al. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome[J].Eur J Endocrinol, 2017, 176: 295-303. doi:  10.1530/EJE-16-0715
    [7] 王林杰, 王鸥, 潘慧, 等.多发性内分泌腺瘤病1型合并垂体腺瘤的临床特点[J].中华神经外科杂志, 2016, 32:266-269. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjwkzz98201603010
    [8] Tatsi C, Stratakis CA.The Genetics of Pituitary Adenomas[J].J Clin Med, 2019, 9: 30. doi:  10.3390/jcm9010030
    [9] Duong CV, Emes RD, Wessely F, et al. Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas[J].Endocr Relat Cancer, 2012, 19: 805-816. doi:  10.1530/ERC-12-0251
    [10] Osamura RY. Tumours of the Pituitary Gland[M]//Lloyd RV, Osamura RY, Klöppel G, et al.WHO Classification of Tumours of Endocrine Organs.4th ed. Lyon: International Agency for Research on Cancer, 2017: 11-64.
    [11] 袁仙仙, 朱惠娟.2017年世界卫生组织垂体肿瘤病理分类变化及临床意义[J].中华内分泌代谢杂志, 2018, 34:623-626. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201807019
    [12] Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience[J].Clin Endocrinol (Oxf), 2009, 71: 92-99. doi:  10.1111/j.1365-2265.2008.03514.x
    [13] Raverot G, Vasiljevic A, Jouanneau E, et al. A prognostic clinicopathologic classification of pituitary endocrine tumors[J].Endocrinol Metab Clin North Am, 2015, 44: 11-18. doi:  10.1016/j.ecl.2014.10.001
    [14] Villa C, Vasiljevic A, Jaffrain-Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal[J].Virchows Arch, 2019, 475: 687-692. doi:  10.1007/s00428-019-02655-0
    [15] Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J].Eur J Endocrinol, 2018, 178: G1-G24. doi:  10.1530/EJE-17-0796
    [16] Ho KKY, Fleseriu M, Wass J, et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement[J].Pituitary, 2019, 22: 569-573. doi:  10.1007/s11102-019-00988-2
    [17] Nasi D, Perano D, Ghadirpour R, et al. Primary pituitary neuroendocrine tumor: Case report and literature review[J].Surg Neurol Int, 2017, 8: 101. doi:  10.4103/sni.sni_450_16
    [18] Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas--diagnosis and emerging treatments[J].Nat Rev Endocrinol, 2014, 10: 423-435. doi:  10.1038/nrendo.2014.64
    [19] 马四海, 姚勇, 代从新, 等.替莫唑胺治疗难治性垂体腺瘤一例报告并文献复习[J].中华神经外科杂志, 2011, 27:484-488. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjwkzz98201105018
    [20] 中国垂体腺瘤协作组, 中华医学会神经外科学分会.中国难治性垂体腺瘤诊治专家共识(2019)[J].中华医学杂志, 2019, 99:1454-1459. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201919005
    [21] Goshtasbi K, Lehrich BM, Abouzari M, et al. Endoscopic versus nonendoscopic surgery for resection of pituitary adenomas: a national database study[J].J Neurosurg, 2020. doi:10.3171/2020.1.JNS193062.[Epub ahead of time].
    [22] Castinetti F.Radiation techniques in aggressive pituitary tumours and carcinomas[J].Rev Endocr Metab Disord, 2020, 21: 287-292. doi:  10.1007/s11154-020-09543-y
    [23] Zhu Y, Shaninian H, Hakimian B, et al.Temodar:novel treatment for pituitary carcinoma[J].US Endocr Soc, 2004, 138:43-45.
    [24] Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J].Eur J Endocrinol, 2018, 178: G1-G24. doi:  10.1530/EJE-17-0796
    [25] Lizzul L, Lombardi G, Barbot M, et al. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature[J].Pituitary, 2020, 23: 359-366. doi:  10.1007/s11102-020-01040-4
  • 加载中
计量
  • 文章访问数:  171
  • HTML全文浏览量:  23
  • PDF下载量:  33
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-20
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!